Back to Archived Journals » Current Biomarker Findings » Volume 4

Current studies of biomarkers for the early diagnosis of rheumatoid arthritis

Authors Chandrashekara S

Received 2 May 2014

Accepted for publication 30 June 2014

Published 1 September 2014 Volume 2014:4 Pages 107—119


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

S Chandrashekara

ChanRe Rheumatology and Immunology Center and Research, Basaveshwaranagar, Bangalore, India

Abstract: Early treatment of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs will improve the outcome significantly. Early diagnosis of RA continues to be a challenge. The disease needs to be distinguished from other self-limiting arthritis and connective tissue disease. Currently available autoantibodies like rheumatoid factors and anticitrullinated cyclic peptide have limited sensitivity and specificity. RA, being a heterogeneous disease, with no unique or distinct defect that has been described, is less likely to have a single pathognomonic marker. There are defined predisposing genetic factors, cell characteristics, cytokine changes, autoantibodies, and products of disease process that have been demonstrated to distinguish rheumatoid from normal and other arthritis. Studies have demonstrated that combinations of factors allow for more specific RA diagnosis; however, when considerations are given to the factors separately, sensitivity increases at the cost of specificity. The present review briefly describes the value of some of the candidate factors and their combinations as diagnostic markers of early RA. Well-designed multicenter studies to evaluate these combinations using a scoring system are recommended for the development of precise and widely applicable biomarkers for early diagnosis of RA.

Keywords: autoantibodies, combination, early RA, specificity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]